FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to optimize response rates and rates of secondary resections of
metastases in patients with initially non-resectable metastatic colorectal cancer of RAS
wildtype. The patients will be treated in two therapy groups:
Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy
with FOLFOXIRI